Abstract 1657: Can LLMs track medication history? GPT-4 outperformed most LLMs in identifying TNFi start/stop events and reasons for switch. 💊 Common reasons for TNFi switching: lack of effectiveness, adverse events, and insurance/cost barriers. @RheumNow #ACR25 https://t.co/5FUR9tBoyu

When MAS is suspected. Soluble IL2 receptor alpha and CXCL9 may be useful (however t cell lymphomas and viral infections like hepatitis may also have them) #ACR25 @RheumNow Key takeaways below https://t.co/wJv1dvwU88

Functional MRI studies have been out there for a while, but mechanisms and significance underlying fMRI findings are unclear fMRI study in 38 active PsA pts w/ significant fatigue Altered functional connectivity between posterior insula to cerebellum & superior frontal gyrus https://t.co/3s9CJUg2uN

Soluble IL2 receptors help assess macrophages behavior. Ferritin also asses the same in Macrophage activation syndrome. ADA2 is the newer biomarker for hemophagocytic syndromes. #ACR25 @RheumNow Interferon gamma also a newer important target in MAS https://t.co/7sWwninBTM

Simultaneous measurements if S100, Ferritin and IL-18 increase diagnostic utility of these biomarkers in Stills disease. @RheumNow #Acr25 https://t.co/3wmijNcpVY

Low percentage of glycosylated Ferritin was more specific for Stills disease but not used frequently in clinical practice. @RheumNow #ACR25 https://t.co/wTK1eIcSKX

#ACR25 Abstr#1532 “The more the merrier” or “Too many cooks..” Preliminary data of CTA313, dual CD19-BCMA CAR-T in 15 #SLE pts showed deep depletion & good response. Global study is planned. Will have to keep on eye on safety (G3 herpes zoster, pneumonia & neutropenia) @RheumNow https://t.co/0KQa9K6bYB

Biomarkers in Stills disease and MAS. #ACR25 @RheumNow IL 6 may not be helpful compared to CRP, and IL 1 beta is difficult to measure IL-18 seems to be the best one. https://t.co/u3oBTd4eaP

#ACR25 Abstr#1608 10! 10! Across the board. 2-yr data from RCT + Open Label showed frequency of both airway and non-airway features of #EGPA improved with Benralizumab/Mepolizumab. Provides assurance to use more in real-world @RheumNow https://t.co/i78xXojGja

IL- 18 go together sometimes with glycolytic enzymes such as aldolase Also MAS may not be a switch on and off mechanism. Lastly MAS with Stills may have increased IL18 levels but not in other disease like SLE #ACR25 @RheumNow https://t.co/BW1fD7usBT

What do we know about IL-18 Normal levels less than 500 Non specific 500 to 15000 Stills (quiet) 2000 to 10000 Mas/glares 20000 and more @RheumNow #ACR25 https://t.co/ZAltAD5Q8V

#ACR25 Abstr#1537 Beyond T-cell malignancy, we should be vigilant re: Local immune effector cell-associated toxicity syndrome (LICATS) with CAR-T. - Mostly afect skin & kidneys - Med time of onset 10 days; duration 11 days -Most LICATS were mild & without sequelae @RheumNow https://t.co/EnAWL936oh

Dr. Gensler gave a fantastic talk on SpA mimics ☝️Not all IBP is axSpA - interpret in the appropriate context + imaging WOF other mimics 🔸 Sacral insufficiency fractures 🔸 Infections 🔸DISH #ACR25 @RheumNow https://t.co/7TIqyp5rYe

In a Brazilian cohort (n=791), axSpA diagnosis delay dropped from 41.7 yrs (1960s) to 1.9 yrs (2020s). Female representation rose to 50%. Non-radiographic axSpA now 16.7%. MRI and updated criteria driving earlier, more equitable recognition. Abstract#1407 @RheumNow #ACR25 https://t.co/8hIpX0a1Sa